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Abstract
Background Artificial intelligence, trained via machine learning (e.g. neural nets and random forests)
or computational statistics algorithms (e.g. support vector machines and ridge regression), holds much
promise for the improvement of small molecule drug discovery. However, structure-activity data are
high dimensional with low signal-to-noise ratios and proper validation of predictive methods is difficult.
Controlling over-fitting remains a major concern. It is poorly understood which, if any, of the currently
available machine learning algorithms will best predict new candidate drugs.
Methods 25 publicly available molecular datasets were extracted from ChEMBL. Neural nets, ran-
dom forests, support vector machines (regression) and ridge regression were then fitted to the structure-
activity data. A new validation method, based on quantile splits on the activity distribution function,
is proposed for the construction of training and testing sets. This is compared to standard random
partitioning of the data. Out-of-sample performance was evaluated using mean squared error and new
two rank-based loss functions which penalize only the predicted ranks of high activity molecules.
Results Model validation based on random partitioning of available data favours models which
overfit and ‘memorize’ the training set, namely random forests and deep neural nets. Partitioning
based on quantiles of the activity distribution correctly penalizes models which can extrapolate onto
structurally different molecules outside of the training data. This approach favours more constrained
models, namely ridge regression and support vector regression. In addition, our new rank-based loss
functions give considerably different results from mean squared error highlighting the necessity to define
model optimality with respect to the decision task at hand.
Conclusions Model performance should be evaluated from a decision theoretic perspective with
subjective loss functions, i.e. loss functions that best encode the modelling goals. Data-splitting based
on the separation of high and low activity data provides a robust methodology for determining the
best extrapolating model. Simpler, traditional statistical methods such as ridge regression outperform
state-of-the-art machine learning methods in this setting.
Introduction
Empirical methodologies guide a significant proportion of early stage small-molecule drug discovery9;20;23.
These range from simple rule based methods (Lipinski’s rule of 5), to searching over molecules ‘similar’
to those already known, to using more complex regression models. This work concerns the objective
evaluation of the predictive ability of the latter, namely statistical and machine learning regression models
trained on molecular structure-activity data. The goal of these models is to characterize the relationship
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between a high-dimensional binary vector representation of small molecules (molecular fingerprint) and
their corresponding target specific in vitro activities. In this context, use of regression modeling is often
known as quantitative structure-activity relationship modeling (QSAR)31;35, and many different model
classes have been used: support vector machines5, ridge regression27, neural nets1;22;27;28 and random
forests34, to name but a few. The success of these models is in part due to high-throughput screening
experiments which produce large structure-activity datasets (order of magnitude 102-106 data-points).
Regression with high-dimensional bioinformatic data is known to be difficult. Problems include the
curse of dimensionality, optimization bias, reporting bias, and low signal-to-noise ratios2;6;16;17;25;32;39.
The main theoretical framework which underpins the use and interpretation of these methods is cross-
validation14;33, which provides an estimate of the predictive error rate6;26. However, validation strategies
based on random partitioning of datasets, either by K-fold cross-validation or the bootstrap, are known to
be optimistic for structure-activity modelling30;36;38. Multiple alternative strategies have been proposed,
for example, splitting by date of assay30, constructing local neighbourhoods based on similarity scores or
scaffold splitting30;38, or stratified sampling whereby equal distributions of the activity levels are assured
across training and testing sets38.
This work also argues that standard validation approaches - K-fold cross-validation and the bootstrap
- which based on random partitioning of available data, will not target the true predictive model error in
the context of small molecule drug discovery. We give a theoretical justification for this claim and show
it empirically using 25 publicly available datasets. We propose a simple alternative partitioning method
which splits datasets on quantiles of the activity distribution function. This univariate parametrisation of
the training set construction allows for inference on the predictive ability of different regression methods
in the limit: as information in the training set is reduced to almost zero. In addition, we argue that
out-of-sample model performance should be evaluated from a decision theoretic perspective29 using loss
functions which reflect as best possible the process of drug discovery. Tailor-made loss functions will
better determine truly optimal model classes compared to standard goodness-of-fit metrics. We propose
simple rank based loss functions to evaluate out-of-sample model prediction accuracy. We show that in
these low signal-to-noise settings7;18;19;21, models with greater structural constraints (ridge regression
and linear kernel support vector regression) outperform less constrained machine learning algorithms
(neural nets and random forests).
Methods
Cross-validation with biased data
Problem setting
This section outlines the formal framework and notation we use throughout the paper. We consider
the general problem of comparing the performance of multiple predictive models (statistical or machine
learning) with respect to a given dataset. ‘Optimality’ of these predictive models is evaluated with
respect to a well defined loss function.
The context investigated here is finding ‘active’ molecules within molecular space. ‘Active’ is defined
as having activity level above a given threshold. This activity is target specific. Conditional on a given
initial dataset, the overall loss (negative utility of the model) is defined as a function of the number of
new molecules needed to be tested until an active molecule is reached.
Each molecule is represented by its ‘molecular fingerprint’, a P -dimensional binary vector. We denote
this as xi = {xji}Pj=1, where i indexes the molecule and j indexes the feature (as referred to in the machine
learning literature) or covariate (statistics literature). We have P = 128 for the fingerprint representation
used in this analysis. Each molecule xi has a target specific activity yi which corresponds to the negative
logarithmic in vitro half-inhibitory concentration (p-IC50: higher values correspond to increased activity).
In this section we ignore the target specificity as each dataset has an associated target and the datasets
are analyzed independently. We do not consider multi-objective regression models here. We denote the
(unknown) functional relationship between the fingerprint and the outcome (activity) as y = G(x) + ,
where  is experimental error.
Given a choice of models M1, ..,MT , respective performances are commonly evaluated using K-
fold cross-validation26;33 (detailed description given in13, Chapter 7), or the bootstrap11, closely re-
lated strategies. Standard K-fold cross-validation proceeds by dividing the data {(xi, yi)}Ni=1 into a
partition of K > 1 equally sized subsets S1, .., SK . For the k
th subset, we train (fit) our model
Mt using the data Strain =
⋃
m 6=k Sm. The out-of-sample expected loss is then estimated by lk =
2
L [{yi}i∈Sk ,Mt({yi}i∈Sk |Strain)]. The overall expected loss estimate is 1K
∑K
k=1 lk. The notation for the
expected loss over each test set is deliberately not summed over the indices of the testing data as this
paper considers non-additive loss functions, e.g. aggregate functions of the testing data. The choice of
the number of folds K is context dependent and relates to a bias-variance trade-off: smaller K implies
a smaller training set and thus increased positive bias in the error rate estimate, however smaller K
also forces greater dis-similarity between the training sets and thus lowers variance in the overall error
estimate. The bootstrap is similar to 3-fold cross-validation, whereby two-thirds of the data are used in
the training set taken as a bootstrap sample of size N (sampling with replacement). Predictive error es-
timation is then done by averaging the out-of-bag errors. The bootstrap generally improves on standard
K-fold cross-validation as it smooths the predictive error when using discontinuous loss functions.
K-fold cross-validation and the bootstrap provide nearly unbiased estimators of the conditional ex-
pected loss if the empirical distribution Fˆx (in this context x denotes a molecule) is an i.i.d. draw from
the true underlying data generating distribution10. In applications where the goal is to accurately predict
the outcome of new data drawn at random with respect to a given data generating process, these are
the correct methods for selecting an optimal predictive model. However, drug (lead candidate) discovery
is better thought of as a complex optimization problem rather than a passive data prediction problem.
The goal here is to generalize (extrapolate) from a model trained on a relatively small dataset to find
active molecules in a high dimensional space (2P possibilities in total).
If the data-generating distribution (e.g. the distribution that has provided the data at hand: think
of this as the protocols which have lead to the data-generating assays) is substantially different from the
uniform distribution over the subset of feasible molecules within the 2P possibilities (this is an unknown
subset), then these validation methods can give a biased estimate of the true out-of-sample loss3;37. For
example, the data might be clustered together (with respect to Manhattan distance over the space of
fingerprints) and therefore the out-of-sample estimate may in fact be highly skewed towards the in-sample
estimate, leading to overconfidence. Molecular structure-activity datasets are highly likely to be skewed
in this way36 and therefore it is necessary to partition the data in such a way that the out-of-sample
testing subset is truly distinct from the in-sample data, thus giving reliable expected loss estimates which
do not favour models that over-fit to the training data. This partition should also reflect the decision
problem at hand.
We next describe non-random data partitions which corrects for clustering of training data.
Activity dependent model validation
The subset of feasible molecules is unknown and this makes it difficult to determine whether a given
training set is ‘close’ to a test set. ‘Close’ needs to be defined with respect to a particular metric. Metrics
such as the Manhattan distance may be a poor proxy of this true (target specific) distance between subsets
of data. Instead, we propose using the observed outcome (activity) y as the discriminant measure between
molecules. Data partitions based on the activity function G (function relating the molecular fingerprint
to the p-IC50) instead of random partitions force dis-similarities between subsets in the partition. If
G(x1) >> G(x2), we assume that x1 is notably experimentally different from x2.
The following validation design is proposed. Let Fˆy be the empirical distribution over the activities
{yi}Ni=1. Let q ∈ (0, 1) be a fixed fraction of the data used to determine the training set. With respect
to the empirical distribution Fˆy, this maps onto an activity threshold Yq (the q
th quantile of Fˆy). The
training set is then constructed by bootstrapping the molecules with activity less than Yq. This is
the opposite of standard balanced or stratified cross-validation where one assures equal distributions of
outcomes across the testing folds4. This is not a ‘cross-validation’ design as the test data are never used
as training data.
Multiple bootstrapped iterations are then computed in order to construct confidence intervals around
the out-of-sample expected loss estimate11. This can be thought of as a stabilizing process within the
validation procedure.
In the following, we assume that the molecule index corresponds to the rank of the activities: y1 ≤
y2 ≤ .. ≤ yN . Let Nq = bN × qc be the number of elements in the training set based on the qth quantile.
For each model Mt, evaluate for a = 1, .., A independent iterations:
• Sample with replacement Nq elements from {xi}Nqi=1 to get a bootstrapped training dataset Xqa .
• Compute la = L
[
{yi}Ni=Nq+1,Mt
(
{yi}Ni=Nq+1|Xqa
)]
, where two proposals for the loss function L
are given in the next section.
The set {l1, .., lA} is then used to estimate the mean expected loss and the 95% confidence intervals.
3
‘Active-rank’ loss function
In the context of using statistical or machine learning methods for novel compound drug discovery, out-
of-sample performance should not directly map onto standard goodness-of-fit measures (e.g. R2 or mean
squared error), but has a simpler decision theoretic interpretation. If these models are to be used in
a real setting then a prediction of high activity for a given feature vector (fingerprint) would lead to a
physical experiment confirming or refuting this prediction. As stated above, the goal is to find molecules
with an activity above a certain threshold (this will be target specific) and therefore each bad prediction
(whereby the true activity is less than the threshold) corresponds to incurring a fixed loss (opportunity-
cost and cost of experiment). In reality, experimental costs will not be constant (some molecules are
more expensive to make than others), however, we simplify the situation to one where each experiment
is considered to have a fixed cost. In the out-of-sample predictions, minimizing the loss corresponds
ranking the active molecules highest. When evaluating the performance of multiple models fitted to a
given dataset, if there is one active molecule and a large number of inactive molecules, the expected loss
is insensitive to the ranking of all the inactives below the rank of the active(s). The model’s fine-grained
accuracy in the region of the inactives is of no importance. This is in contrast to standard measures of
predictive accuracy and loss such as R2, mean squared error, or receiver operating characteristics (AUC)
which have previously been used in this context9;15;30;34;36;38.
We define our ‘active-rank’ loss function as follows. We choose a fraction γ ∈ (0, 1), corresponding
to a threshold activity Yγ with respect to the empirical distribution function FˆY . In practice γ would be
close to 1 (e.g. in the range 0.9-0.99) to simulate scenarios where actives molecules are rare and inactives
common. The subset of molecules {xi}Ni=Nγ are then defined as ‘actives’. We define Nγ = bNγc (the
total number of actives), and Ntest = N −Nq (the size of the test set).
For the model Mt fit to the training data X
q, the out-of-sample loss is defined with respect to the
ranks assigned to the out-of-sample active molecules. We take as convention that the ranks assigned
to the test data go from 0 (molecule with highest predicted activity) to Ntest − 1 (molecules with least
predicted activity). The loss which only depends on the rank of the highest ranked active is defined as:
Lγmin =
1
Ntest −Nγ minj=Nγ ..Ntest RankMt(xj) (1)
The minimum active rank will vary from 0 (an active molecule is ranked top in the test data), to
Ntest −Nγ (all the Nγ active molecules are ranked last). We normalize to obtain a loss function defined
over the interval [0, 1]. An alternative version of this loss, whereby all the ranks of the active molecules
are taken into account, thus penalizing sub-optimal ranking for all active molecules, is given by:
Lγsum =
1
Nγ(Ntest −Nγ)
Ntest∑
j=Nγ
RankMt(xj)−Nγ(Nγ − 1)/2
 (2)
The sum of the active ranks will vary from Nγ(Nγ − 1)/2 (all actives are ranked in the top Nγ
molecules) to Nγ(Ntest −Nγ) (all actives are ranked in the last Nγ molecules).
We note that when Nγ = 1, e.g there is only 1 active molecule, L
γ
min = L
γ
sum.
As mentioned above, both these loss functions are non-additive with respect to the testing data.
Statistical analysis
All statistical analyses were done in Python version 2.7. The entire analysis is fully reproducible via a
publicly available Python Jupyter notebook found at https://github.com/owatson/QuantileBootstrap.
Regression models
We evaluated the performance of four model classes:
• Support vector regression (Python module: sklearn, function SVR)
• Random forests (Python module: sklearn, function RandomForestRegressor)
• Linear ridge regression (Python module: sklearn, function Ridge)
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• Deep neural networks (Python module: sklearn, functions Pipline and StandardScalar, and Python
module: keras, function KerasRegressor)
For support vector regression we used a linear kernel. For random forests we used the default
parameter settings, growing 100 trees each with a maximum tree depth of 10 splits. For linear ridge
regression we used a penalty term of α = 0.1. For deep neural networks we first standardised the data,
then used two dense layers, the first of dimension 128 (to match the input feature dimension) and then
dimension 16, both with relu activation.
These correspond to standard default choices in the literature. These four model classes are all
somewhat insensitive to tuning parameters. In order to minimize any optimization bias, we did not
attempt to tune any of the parameters to the set of datasets at hand, except for the deep learning
models, where we first fit 4 model structures and chose the model with lowest out-of-sample mean
squared error using bootstrapped data.
Model comparison
We first compared model performances using 5-fold cross-validation (this uses 80% of data chosen at
random to predict the remaining 20%) and bootstrapping (this uses approximately two thirds of the
data to predict the remaining third). With discontinuous loss functions, bootstrapping smooths the
out-of-sample error predictions11. The out-of-sample predictions were evaluated using mean squared
error, and both active-rank loss functions Lγmin, L
γ
sum. For the active-rank loss functions, we evaluated
out-of-sample loss using 3 separate γ thresholds corresponding respectively to labelling 10, 5 and 1% of
the test data as active.
We then ran our activity dependent validation procedure using progressively lower fractional thresh-
olds for the training data: q = 0.9; 0.8; 0.6; 0.4. The same three γ thresholds were used to evaluate the
out of sample expected losses for the active-rank loss functions. All predictions were evaluated with
mean squared error and both active-rank loss functions.
Overall performance was evaluated by assuming independence between the 25 datasets. The total
model score assigned to each model Mt is defined as the sum over all datasets of the probabilities that
the Mt had lowest expected loss (probability of optimality). As the number of bootstrap iterations is
much lower than then total number of possible iterations (N
Nq
q ), we use the jackknife to calculate the
standard error on the mean out-of-sample prediction. 400 bootstrap iterations were used for each model
and set of problem definition parameters, i.e. the pair of parameters (q, γ).
Data
Data curation
We extracted IC50 data from ChEMBL database version 23 for 25 diverse protein targets and receptors.
In order to assemble high-quality data sets, we only considered IC50 values for compounds that satisfied
the following filtering criteria: (i) an activity unit equal to ‘nM’, (ii) activity relationship equal to ‘=’,
(iii) target type equal to SINGLE PROTEIN, and (iv) organism equal to Homo sapiens. Bioactivity
values were modeled in a logarithmic scale (i.e., pIC50 = log10 IC50). The average pIC50 value was
calculated for protein-compound pairs with multiple IC50 measurements available.
Further details about the data sets are provided in Table 1. A comparative analysis of these datasets
has previously been done in the context of iterative model fitting8. All data used in this paper (activity
levels, 128-bit fingerprints and smiles) are available at:
https://github.com/owatson/QuantileBootstrap.
Molecular representation
The python module Standardiser was used to standardise all chemical structures. Inorganic molecules
were removed, and the largest fragment was kept in order to filter out counterions.
We computed circular Morgan fingerprints 52 using RDkit (release version 2013.03.02). The radius
was set to 2 and the fingerprint length to 128.
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Table 1: 25 publicly available datasets extracted from ChEMBL and analysed in this paper.
Target preferred name Target abbreviation Uniprot ID ChEMBL ID #Bioactive molecules
Alpha-2a adrenergic receptor A2a P08913 1867 203
Tyrosine-protein kinase ABL ABL1 P00519 1862 773
Acetylcholinesterase Acetylcholin P22303 220 3159
Androgen Receptor Androgen P10275 1871 1290
Serine/threonine-protein kinase Aurora-A Aurora-A O14965 4722 2125
Serine/threonine-protein kinase B-raf B-raf P15056 5145 1730
Cannabinoid CB1 receptor Cannabinoid P21554 218 1116
Carbonic anhydrase II Carbonic P00918 205 603
Caspase-3 Caspase P42574 2334 1606
Thrombin Coagulation P00734 204 1700
Cyclooxygenase-1 COX-1 P23219 221 1343
Cyclooxygenase-2 COX-2 P35354 230 2855
Dihydrofolate reductase Dihydrofolate P00374 202 584
Dopamine D2 receptor Dopamine P14416 217 479
Norepinephrine transporter Ephrin P23975 222 1740
Epidermal growth factor receptor erbB1 erbB1 P00533 203 4 868
Estrogen receptor alpha Estrogen P03372 206 1705
Glucocorticoid receptor Glucocorticoid P04150 2034 1447
Glycogen synthase kinase-3 beta Glycogen P49841 262 1757
HERG HERG Q12809 240 5207
Tyrosine-protein kinase JAK2 JAK2 O60674 2971 2655
Tyrosine-protein kinase LCK LCK P06239 258 1352
Monoamine oxidase A Monoamine P21397 1951 1379
Mu opioid receptor Opioid P35372 233 840
Vanilloid receptor Vanilloid Q8NER1 4794 1923
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COX-1
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Glucocortic
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Figure 1: Model comparison using the standard bootstrap. Expected model out-of-sample mean
squared error shown for each dataset, ordered from left to right by increasing size of dataset. Error
bars correspond to ± 2 standard errors around the expected loss estimate, computed using the jackknife
estimator. For each datatset, the optimal model is the one with least expected loss, with random forests
scoring best for every single dataset.
6
Results
Model performance evaluated using random data partitioning
Random partitioning of the data, either using 5-fold cross-validation (training set contains 80% of the
data) or bootstrapping (training set contains two thirds of the data) clearly shows that random forests and
deep learning have the best out-of-sample performance (for full results see github Jupyter noteboook).
The bootstrap partitioning has the advantage of variance reduction showing clearer trends over the 25
datasets (Figure 1). Random forests performs best on almost every dataset when scored using mean
squared error (Figure 2, bottom right panel), and performs on average as well as deep learning when
scored with the active-rank loss functions (Figure 2, first 3 panels). Ridge regression and support vector
regression are never optimal in this setting across the 25 datasets, irrespective of the loss function. Figure
1 shows the bootstrap out-of-bag performance as evaluated by mean squared error for the 4 models over
the 25 datasets, with datasets ordered from smallest to largest. Ridge regression has largest out-of-bag
error, followed by support vector regression and then deep learning and random forests. This ranking
holds for every dataset.
These out-of-sample performances closely reflect the in-sample error. Both deep learning and random
forests can almost ‘memorize’ the data with in-sample losses close to zero (see Jupyter notebook).
Target activity dependent cross validation
Decreasing the quantile activity threshold for the training data from 1 (all data are used in the bootstrap
construction of the training set) to 0.4 (only 40% of the data ordered by activity are used in the bootstrap
construction of the training set) results in a complete reversal of optimality amongst the 4 predictive
models. When scoring models by out-of-sample mean squared error, support vector regression becomes
optimal for quantiles below 0.75 (Figure 2, bottom right panel).
For the active-rank loss functions, lowering the activity training threshold also induces a reversal of
model optimality (change-point for q ≈ 0.8). In the most extreme setting (q = 0.4), support vector
regression and ridge regression perform approximately equally well, with total scores corresponding to
optimality on half of the datasets. This performance is shown in detail in Figure 3, with datasets
ordered from left to right by increasing size. There is some heterogeneity between the datasets for model
optimality, but the overall trends are clearly in favour of ridge regression and support vector regression.
By averaging over the 25 datasets, we can see that these trends are robust with respective the target
used as the outcome measure in the regression models.
Importance of the loss function
There are clear disparities between model evaluations for the different loss functions. Mean squared
error favours random forests in the standard setting (q = 1), and support vector regression in the
restricted activity setting (q < 0.6). However, the active-rank loss functions favour equally deep-learning
and random forests in the standard setting, and support vector regression and ridge regression in the
restricted activity setting. Moreover, the results differ between Lγmin and L
γ
sum. The out-of-sample
performance of ridge regression is consistently better when evaluated using Lγmin, and that of support
vector regression is consistently better when evaluated using Lγsum (Figure 2). These results show that
the evaluation of model performance is highly dependent on the loss function used. This directly reflects
how the different loss functions penalize predictive performance, with Lγmin only penalizing the rank of
the first active molecule.
Discussion
There is considerable hype around the use of AI to find novel drug candidates and to optimize early-
stage drug discovery12. Deep-learning via the use of deep neural networks is a highly active research
area with a wide range of applications and proven success stories. However, neural networks are known
to be extremely ‘data-hungry’ and work best in high signal-to-noise settings24. For regression modelling
using molecular structure-activity data, we do not believe deep-learning models will perform well in
predicting novel areas of molecular space of high activity, contrary to recent claims22. This modelling
exercise shows that partitioning on quantiles of the activity distribution, and thereby mimicking the
process of extrapolating onto previously unseen areas of molecular space, removes all predictive power
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Figure 2: Comparison of overall model performance for the standard bootstrap and the
restricted activity bootstrap. All four panels show the overall model score (sum of the probabilities
of model optimality over the 25 datasets) as a function of the restriction on the activity levels in the
training data. 100% corresponds to standard cross-validation (random partitioning). The first three
panels show the results for the active-rank loss functions (Lγmin shown by dotted lines; L
γ
sum shown by
dot-dash lines) with values of γ going from 0.9 (top left) to 0.99 (bottom left). The bottom right panel
shows the results when models are scored using mean squared error. Red: deep learning; blue: support
vector regression; orange: random forests; green: ridge regression.
from the deep learning models. This approach can be contrasted with ‘temporal splitting’ whereby
datasets are partitioned by assay date, the first section used to train the model, the second to test.
Although this makes intuitive sense and could be argued to mimic real-life settings, it doesn’t guarantee
that highly similar molecules - both in structure and activity - will not be found across both testing
and training data. Nor does it directly test the capability of a statistical or machine learning model to
detect signal predicting activity gradients, resulting in good predictions of molecules with high activity.
Splitting on activity quantiles deals with these issues, and provides a simple and interpretable univariate
parametrisation of the information content used to train the model.
Evaluation of the predictive performance of regression models when applied to small molecule structure-
activity datasets necessitates different approaches than in the standard bioinformatic and high-dimensional
settings. Online prediction problems (e.g. image classification, spam filtering, recommender systems, etc)
and statistical inference problems (e.g. genome-wide studies, biomarker discovery, micro-array analysis)
have different goals. In the drug discovery context, we start with a small training set (N << 2P ) and
attempt to extrapolate outside of these data in order to find molecules which are inherently ‘different’
from those in the training data. In the machine learning and computational statistics literature, this
is most similar to an optimization problem or gradient ascent problem. This search procedure is done
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Figure 3: Model comparison using the restricted activity bootstrap with γ = 0.4. Model
expected out-of-sample Lγ=0.99min loss shown for each dataset, ordered from left to right by increasing size
of dataset. Error bars correspond to ± 2 standard errors around the expected loss estimate, computed
using the jackknife estimator. For each datatset, the optimal model is the one with least expected loss.
in a relatively resource constrained setting (cost of experimentation, time cost) and therefore model
evaluation should be decision theoretic with a subjective loss29.
We expect our active-rank loss functions to differ in performance from standard machine learning
type losses (most commonly this would be mean squared error). The active-rank loss functions Lγmin
and Lγsum do not penalize bad predictions outside of the subspace of interest, i.e. high activity areas of
molecular space. However, a current limitation of the proposed methods is that the loss functions are
non-additive and therefore cannot be used to penalize model fitting in the training phase. This is subject
of future work. Other limitations of the work are that we have done little to no internal model parameter
tuning, except for deep neural nets to assess structures most appropriate for these type of data. However,
we do not expect parameter tuning to considerably change the results nor the conclusions of the study.
Furthermore, all the analyses are easily reproducible with our openly available Jupyter notebook, thus
easily extended to new computational algorithms, different parameter settings, or new datasets. Lastly,
the loss functions used to evaluate model performance on these benchmark datasets will not estimate
the true out-of-sample expected loss in experimental settings. In reality, true γ thresholds (percentage
of feasible molecules above a certain activity level) could be multiple orders of magnitude larger than
those used in our study (e.g. the top 10−10% of the testing data).
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